Technical analysis of Fate Therapeutics, Inc. (FATE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Price Performance
| 1 month | -4.69% |
| 3 months | +16.75% |
| Year-to-date | +148.32% |
| 1 year | +156.84% |
| 3 years | -4.31% |
| 5 years | -96.59% |
52-Week Range
| 52-week High | $3.23 |
| 52-week Low | $0.94 |
| Avg Volume (90d) | 3.1M |
Technical Indicators
| SMA 50 | $2.58 |
| SMA 200 | $1.77 |
| Beta | 2.24 |
| 30-day Volatility (annualised) | 61.5% |
| Price vs SMA 50 | -5.5% |
| Price vs SMA 200 | +37.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.35 | |
| 2025-11 | $1.14 | -15.6% |
| 2025-12 | $0.98 | -13.8% |
| 2026-01 | $1.19 | +21.1% |
| 2026-02 | $1.48 | +24.4% |
| 2026-03 | $1.20 | -18.9% |
| 2026-04 | $1.25 | +4.2% |
| 2026-05 | $2.84 | +127.2% |
| 2026-06 | $2.70 | -4.9% |
| 2026-07 | $2.45 | -9.3% |
| 2026-08 | $2.39 | -2.4% |
| 2026-09 | $2.44 | +2.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $2.44 |
| Market Cap | $284M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | -2.84 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.49 |
| Current Ratio | 4.85 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -6.97 |